Hello, Fool! | Login | Signup | My Fool
Jul 23, 2008 5:42 PM ET | Site Changes | Help
Search: Tickers Company Names Players
A biopharmaceutical company committed to improving the lives of people with diabetes, obesity and other diseases through the discovery, development and commercialization of innovative medicines.
View Ticker Page (AMLN)
Results 11 - 20 of 55 : 12345Next »
Recs
rangercapt (70.71) Submitted: 12/11/06 7:58 PM : Start Price: $38.58 AMLN Score: -14.33
AMLN is more then just a diabetes treatment. It is going to evetually provide enough information to prevent it from getting worse and may reverse this deadly disease. Other companies are trying to make inhalable insulin when they should be trying t...
Report this Post Replies: 0 | Reply | Permalink
Oops! There appears to be a problem with your comment. Check to see if there's something you left out.
donklenzman (91.70) Submitted: 9/14/06 10:25 AM : Start Price: $46.08 AMLN Score: -33.40
20+million diabetics
vgettinger (< 20) Submitted: 9/24/06 10:45 PM : Start Price: $44.15 AMLN Score: -30.78
This company makes two medications currently on the market for Diabetes. However, one of their effects is the potential for significant weight loss. I believe that Byetta for Type 2 DM will be used within one year to prevent diabetes in at risk indiv...
Report this Post Replies: 1 | Reply | Permalink
jack0071 (73.44) Submitted: 9/15/06 7:23 AM : Start Price: $45.87 AMLN Score: -32.76
"Miracle" drugs for diabetics. Sales increasing for the forseeable future. Deep pipeline. Super management.
SmartasaRaven (52.20) Submitted: 12/19/07 10:34 PM : Start Price: $37.17 AMLN Score: -8.27
GREAT PIPELINE
Gr8Vette (88.60) Submitted: 9/15/06 6:08 PM : Start Price: $44.75 AMLN Score: 31.00
One horse show with Byetta. Has had its run up from $16/share to $47/share.
bill51347 (63.61) Submitted: 11/26/07 5:53 PM : Start Price: $38.80 AMLN Score: 14.73
Great products, poor management.
nepedal (76.68) Submitted: 9/21/06 5:29 PM : Start Price: $45.66 AMLN Score: -32.52
Byetta is the real deal in diabetes treatment. Everything else in this company (and there's some) is gravy to an investor. As all paradigmatic shifts, Byetta will take time but I think it'll be worth the wait.
Perkeo (94.41) Submitted: 9/22/07 1:33 AM : Start Price: $49.60 AMLN Score: -24.88
Get R&D pipeline.
Ludraman1 (66.96) Submitted: 9/18/07 5:45 PM : Start Price: $48.17 AMLN Score: -22.58
a risky one, but a bet on diabetes and obesity.
Terms & Conditions
RSS Headlines
Fool UK